Trial · NCT01350388
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Thiobarbituric Acid Reactive Substance (TBARS) Concentration in Adipose Tissue From Baseline to 24 Weeks | Febuxostat | 34.0 | 95% Confidence Interval -26.3 to 143.4 | percent difference in geometric mean | |
| Change in Thiobarbituric Acid Reactive Substance (TBARS) Concentration in Adipose Tissue From Baseline to 24 Weeks | Placebo | 44.6 | 95% Confidence Interval -19.3 to 159.2 | percent difference in geometric mean | |
| Change in Adiponectin Concentration in Adipose Tissue From Baseline to 24 Weeks | Febuxostat | 2.3 | 95% Confidence Interval -23.4 to 36.7 | percent difference in geometric mean | |
| Change in Adiponectin Concentration in Adipose Tissue From Baseline to 24 Weeks | Placebo | -4.1 | 95% Confidence Interval -27.7 to 27.4 | percent difference in geometric mean | |
| Change in Urinary Concentrations of Transforming Growth Factor-beta1 (TGF-beta1) From Baseline to 24 Weeks | Febuxostat | 29.8 | 95% Confidence Interval 4.4 to 61.5 | percent difference in geometric mean | |
| Change in Urinary Concentrations of Transforming Growth Factor-beta1 (TGF-beta1) From Baseline to 24 Weeks | Placebo | 10.0 | 95% Confidence Interval -10.8 to 35.6 | percent difference in geometric mean | |
| Change in Tumor Necrosis Factor-α (TNF-α) Concentration in Plasma From Baseline to 24 Weeks | Febuxostat | -9.9 | 95% Confidence Interval -30.6 to 16.8 | percent difference in geometric mean | |
| Change in Tumor Necrosis Factor-α (TNF-α) Concentration in Plasma From Baseline to 24 Weeks | Placebo | -7.4 | 95% Confidence Interval -28.3 to 19.7 | percent difference in geometric mean | |
| Change in Interleukin-6 (IL-6) Concentration in Plasma From Baseline to 24 Weeks | Febuxostat | -24.0 | 95% Confidence Interval -35.3 to -10.7 | percent difference in geometric mean | |
| Change in Interleukin-6 (IL-6) Concentration in Plasma From Baseline to 24 Weeks | Placebo | -9.5 | 95% Confidence Interval -22.7 to 6.1 | percent difference in geometric mean | |
| Change in High Sensitivity C-Reactive Protein (hsCRP) Concentration in Plasma From Baseline to 24 Weeks | Febuxostat | 12.2 | 95% Confidence Interval -16.3 to 50.3 | percent difference in geometric mean | |
| Change in High Sensitivity C-Reactive Protein (hsCRP) Concentration in Plasma From Baseline to 24 Weeks | Placebo | -7.2 | 95% Confidence Interval -30.5 to 23.8 | percent difference in geometric mean |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01350388/results